Gilead Sciences GILD Descovy — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gilead Sciences in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Gilead Sciences’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gilead Sciences's descovy — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gilead Sciences's descovy — total revenues?
- Gilead Sciences (GILD) reported descovy — total revenues of $807M in Q1 2026.
- How has Gilead Sciences's descovy — total revenues changed year-over-year?
- Gilead Sciences's descovy — total revenues increased by 37.7% year-over-year, from $586M to $807M.
- What is the long-term trend for Gilead Sciences's descovy — total revenues?
- Over 4 years (2021 to 2025), Gilead Sciences's descovy — total revenues has grown at a 12.9% compound annual growth rate (CAGR), from $1.7B to $2.76B.
- What does descovy — total revenues mean?
- The total sales revenue generated by a specific HIV medication product line.
- How do you interpret descovy — total revenues?
- An increase indicates strong market demand, successful patient retention, or effective pricing strategies for the therapy. A decrease may signal increased competition from generics, shifts in clinical treatment guidelines, or the natural maturation of the product lifecycle.
- How does descovy — total revenues compare across companies?
- Comparable to product-specific revenue reporting for branded pharmaceutical therapies in the infectious disease or oncology sectors at peer biopharmaceutical companies.